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Abstract: A nationwide cross-sectional study, LIPIDOGRAM2015, was carried out in Poland in the
years 2015 and 2016. A total of 438 primary care physicians enrolled 13,724 adult patients that sought
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medical care in primary health care practices. The prevalence of hypertension, diabetes mellitus,
dyslipidaemia, and CVD were similar in urban and rural areas (49.5 vs. 49.4%; 13.7 vs. 13.1%;
84.2 vs. 85.2%; 14.4 vs. 14.2%, respectively). The prevalence of obesity (32.3 vs. 37.5%, p < 0.01) and
excessive waist circumference (77.5 vs. 80.7%, p < 0.01), as well as abdominal obesity (43.2 vs. 46.4%,
p < 0.01), were higher in rural areas in both genders. Mean levels of LDL-C (128 vs. 130 mg/dL,
p = 0.04) and non-HDL-C (147 vs. 148 mg/dL, p = 0.03) were slightly higher in rural populations.
Altogether, 14.3% of patients with CVD from urban areas and 11.3% from rural areas reached
LDL <70 mg/dL (p = 0.04). There were no important differences in the prevalence of hypertension,
diabetes, dyslipidaemia, and CVD, or in mean levels of blood pressure, cholesterol fractions, glucose,
and HbA1c between Polish urban and rural primary care patient populations. A high proportion of
patients in cities and an even-higher proportion in rural areas did not reach the recommended targets
for blood pressure, LDL-C, and HbA1c, indicating the need for novel CVD-prevention programs.
Keywords: primary health care; cardiovascular diseases; risk factors; urban; rural; Poland
1. Introduction
Differences in healthcare access, utilisation, and health status between rural and urban
populations are described in the medical literature [1,2]. Cardiovascular diseases (CVD)
are the leading causes of death and disability globally [3]. Well-known cardiovascular (CV)
risk factors include elevated blood pressure (BP), dyslipidaemia, hyperglycaemia, obesity,
and smoking. The prevalence of CVD and CV risk factors is high in Central and Eastern
European (CEE) countries [4]. Currently, in Poland, over 15% of the patients attending
primary health practices are diagnosed with CVD, over 60% have hypertension (HTN),
over 80% are dyslipidemic, and approximately 15% of patients are diagnosed with diabetes
mellitus (DM) [5].
Differences in CVD prevalence and levels of CV risk factors between urban and rural
regions have been confirmed all across Europe [6–9]. Additionally, the Prospective Urban
Rural Epidemiology (PURE) Study (which enrolled 156,424 persons from 3 high-income,
10 middle-income, and 4 low-income countries) reported higher rates of CV events in rural
than urban areas in middle-income and low-income countries. By comparison, there were
no such differences in high-income countries. However, at the same time, the prevalence of
the CV risk factors was higher in urban than in rural communities [10].
Despite the high prevalence of CV risk factors, achieving the recommended levels of
cholesterol fractions, blood pressure, and glucose remains challenging. The authors of the
DA VINCI study revealed that 54% of patients achieved their risk-based LDL-C goals [11].
Meanwhile, data from the TERCET registry indicate that after ST-elevated myocardial
infarction (STEMI), 32.4% of patients achieved LDL-C < 70 mg/dL, compared to 29.9%
patients after a non-ST elevated myocardial infarction (NSTEMI) [12].
Due to health inequities between urban and rural regions, place of residence remains
one of the essential determinants of health [9]. Nevertheless, it is not currently known
whether urban–rural differences exist in the prevalence of CV risk factors and the achieve-
ment of therapeutic goals in Poland and some other CEE countries.
The aim of this study was to analyse the differences between the patients attending
primary health care (PHC) practices located in urban and rural settings in Poland in
reference to (1) the prevalence of CV risk factors and CVD and (2) the proportion of
individuals achieving therapeutic goals in the treatment of HTN, dyslipidaemia, and DM.
2. Materials and Methods
We conducted a secondary analysis of the data from the nationwide cross-sectional
study LIPIDOGRAM2015, which was carried out in Poland in the fourth quarter of 2015
and first and second quarters of 2016 [13]. A group of 438 physician-investigators in 398
practices were selected in a manner proportional to the number of inhabitants in 16 Polish
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major administrative regions. The study actively enrolled 13,724 adult patients seeking
medical care for any medical reason in PHC practices. Details of sampling, selection, and
measurement methods have been described previously [5,13]. Briefly, for each participant
in the study, the physician-investigator completed a 28-item questionnaire, which gathered
basic demographic (age, gender, level of education, place of residence) and clinical (chronic
diseases, lifestyle habits including diet, physical activity, smoking status, family history
of CVD, and current pharmacotherapy) data. Anthropometric measurements were made
(height, body weight, waist circumference, and hip circumference) and the body mass
index (BMI) was calculated. On the same day, measurements of BP, heart rate, and fasting
glucose were taken. Blood samples were collected for measurement of the lipid profile.
Glycated haemoglobin was assessed in a subgroup of patients (random sample of up to
four patients in each PHC practice).
2.1. Definitions and Classification
HTN, DM, and dyslipidaemia were defined according to the relevant guidelines that
were in force in 2015 [14–16].
Participants were classified as having HTN, DM, and dyslipidaemia when: (1) those
diseases were previously diagnosed; or (2) patient used at least one hypotensive, lipid-
lowering or hypoglycaemic medication, respectively. Participants were also defined as
having HTN when office SBP was ≥140 mmHg and/or office DBP was ≥90 mmHg (average
from two measurements). Participants were also defined as having dyslipidaemia when
the measured LDL-C level was ≥115 mg/dL and/or TG level was ≥150 mg/dL.
The presence of coronary heart disease, previous myocardial infarction, atrial fibrilla-
tion, ischemic or haemorrhagic stroke, and medications the patients used were reported in
the questionnaire by the physician who cared for the patient.
We used the WHO classification of obesity, based on BMI [17] and the norms of
the International Diabetes Federation (IDF) for waist circumference (<80 cm in women
and <94 cm in men) [18]. Overweight was defined as BMI 25.0–29.9 and obesity ≥30.0,
respectively. We defined abdominal obesity as a waist–hip ratio (WHR) ≥ 1 for men and
WHR ≥ 0.85 for women [19].
Patients who smoked at least one cigarette per day on the day of inclusion in the study
were classed as current smokers. Patients who had smoked at least 100 cigarettes in their
lifetime, quit smoking, and did not smoke on the day of inclusion in the study were classed
as ex-smokers. Patients who never smoked cigarettes were classed as non-smokers.
Therapeutic goals for HTN (SBP < 140 mmHg and DBP < 90 mmHg), DM (HbA1c < 7%),
and dyslipidaemia (patients with CVD: LDL-C < 70 mg/dL, non-HDL-C < 85 mg/dL)
were established on the basis of the guidelines in place in 2015 [14–16]. The analyses were
extended to include the therapeutic goals proposed in relevant guidelines that appeared
in subsequent years, i.e., the guidelines on hypertension (2018) [20] and dyslipidaemia
(2019) [21].
2.2. Statistical Analyses
Mean values, standard deviations, proportions of risk factors, and treatment used
are presented and compared between the patients from urban and rural areas using Pear-
son’s chi-square or Mann–Whitney U or Student’s t-tests, as appropriate. The relationship
between the patients’ characteristics and their achievement of lipid-lowering goals, hy-
pertension, and diabetes therapy was examined separately for urban and rural areas, and
each variable was analysed individually. Logistic regression was used to investigate the
relationship between all independent variables and achievement of: (1) lipid-fraction target
levels, (2) blood-pressure target levels, (3) glucose and HbA1c target levels.
Odds ratios (OR) and 95% confidence intervals (CI) are presented. P-values below 0.05
were considered significant. All statistical analyses were conducted using the STATISTICA
programme, version 13.3.
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3. Results
3.1. Patient Characteristics
The LIPIDOGRAM2015 study included 13,724 patients (7028 residents of urban and
6696 rural areas, respectively). The average age was 56 years (57 in urban and 56 in rural
populations; p < 0.01). The average age of women living in cities was 2 years older than
those living in rural settings (p < 0.01). The level of education was higher in urban areas in
both genders (p < 0.01). Demographic characteristics of enrolled patients (categorised by
gender and place of residence) are presented in Table 1.
Table 1. Participant clinical characteristics.
All Women Men
Urban Rural p Urban Rural p Urban Rural p

























































X ± SD (mmHg) 132 ± 18 133 ± 19 0.01 130 ± 18 131 ± 19 0.05 136 ± 19 135 ± 17 0.14
DBP
X ± SD (mmHg) 80 ± 10 81 ± 11 0.00 79 ± 10 80 ± 11 0.00 83 ± 11 82 ± 10 0.03
TC X ± SD (mg/dL) 202 ± 44 203 ± 45 0.21 205 ± 44 205 ± 43 0.92 199 ± 47 196 ± 44 0.02
HDL − C X ± SD
(mg/dL)
55 ± 15 55 ± 15 0.02 59 ± 15 58 ± 15 0.00 48 ± 13 48 ± 13 0.14
LDL − C X ± SD
(mg/dL)
128 ± 40 130 ± 41 0.04 129 ± 41 130 ± 41 0.23 129 ± 40 126 ± 39 0.05
non−HDL−C X ± SD
(mg/dL)
147 ± 42 148 ± 43 0.03 146 ± 42 147 ± 41 0.24 151 ± 45 148 ± 42 0.04
TG X ± SD (mg/dL) 147 ± 113 149 ± 124 0.79 135 ± 97 135 ± 83 0.83 174 ± 170 169 ± 133 0.78
Glycaemia X ± SD
(mg/dL)
104 ± 25 103 ± 25 0.048 102 ± 24 102 ± 23 0.07 106 ± 27 106 ± 27 0.27
HbA1c X ± SD (%) 5.7 ± 1 5.7 ± 1 0.61 5.7 ± 0.9 5.7 ± 0.9 0.83 5.8 ± 1 5.8 ± 1 0.39
































































J. Clin. Med. 2021, 10, 5656 5 of 12
Table 1. Cont.
All Women Men
Urban Rural p Urban Rural p Urban Rural p












FH 32 (0.46%) 41 (0.61%) 0.21 25 (0.56%) 27 (0.64%) 0.60 7 (0.28%) 14 (0.56%) 0.12























circumference (W ≥ 80





























































p < 0.05 was considered statistically significant. SD: standard deviation, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: total
cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TG: triglycerides, HbA1c: glycated
haemoglobin, CVD: cardiovascular disease, CHD: coronary heart disease, MI: myocardial infarct, AF: atrial fibrillation. To receive values in
mmol/L: (1) for TC, HDL-C, and LDL-C divide the value in mg/dL by 38.67; (2) for TG divide the value in mg/dL by 88.57.
3.2. Risk factors and Cardiovascular Diseases
There were no statistical differences between the mean levels of total cholesterol,
triglycerides, glucose, and HbA1c in patients living in urban and rural areas. Mean systolic
and diastolic BP was 1 mmHg higher in the rural residents (a statistically significant
difference). HDL-C concentration was statistically higher in the urban female population
and non-HDL-C level in the urban male population. The prevalence of hypertension, DM,
dyslipidaemia, and CVD was similar in urban and rural areas. The prevalence of obesity
and excessive waist circumference (77.49% vs. 80.66%, p < 0.01), as well as abdominal
obesity (43.18 vs. 46.40%, p < 0.01), were higher in rural areas in both genders. However,
there was no such trend in the overweight category—in men, the prevalence was higher in
the urban population, while in women, the differences were not statistically significant. In
addition, women living in rural areas smoked less frequently than those in urban areas (a
statistically significant difference), while the differences in smoking status in men were not
statistically significant. Detailed data are presented in Table 1.
There were also no statistically significant differences in the use of lipid-lowering
therapies, antihypertensives, or most diabetic medications between patients living in urban
and rural areas. The most frequently used lipid-lowering medicine were: atorvastatin,
simvastatin, and rosuvastatin. Diabetes was treated mostly with metformin. The groups of
antihypertensive drugs most commonly used in PHC practices were ACEI, diuretics, and
B-blockers. Glipizide was significantly more frequently used in the female rural population.
Detailed values are presented in Table S1.
3.3. Achievement of Therapeutic Goals
A proportion of 40% of patients (both in urban and rural areas) without diagnosed
diabetes had elevated fasting glucose levels. More than 55% of diabetic patients achieved
HbA1c < 7% (Figure 1).
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Roughly three quarters of patients ithout diagnosed hypertension had BP belo
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targets (according to guidelines in force at the time the study was conducted) (p < 0.01).
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lished after the study period), we discovered that new treatment targets were achieved in
approximately 5% of patients. Detailed data are presented in Figure S1.
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Figure 2. Percentage of patients ithout hypertension ith nor al blood-pressure level and hyper-
t si ti ts r i tr t t ls.
Over 36% of all patients without CVD had LDL-C < 115 mg/dL. In this group, around
22% had LDL-C < 100 mg/dL. Almost half of the patients reached non-HDL-C < 145 mg/dL,
and around 2/3 of patients had TG < 150 mg/dL. The differences between urban and rural
populations were not statistically significant (Figure 3). Fourteen per cent of patients with
CVD from urban areas and 11% from rural areas reached LDL < 70 mg/dL (p = 0.04). The
differences between urban and rural populations were st tistic lly significant only in males
(18% in urban areas vs. 12% in rural a e s, p < 0.01). There were also statistically significant
differences betw en the percentage of patients with CVD reaching therap utic goals of
non-HDL-C in the urban and rural male population (11.21 vs. 7.32%, p = 0.04) (Figure 3).
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p < 0.05 was considered statistically significant. OR: odds ratio; CI: confidence interval; CVD: cardiovascular disease.
4. Discussion
4.1. Main Findings
We found no important differences in the prevalence of hypertension, DM, dyslipi-
daemia, or CVD in urban and rural adult populations attending primary care in Poland.
Nor did we find differences in mean levels of glucose or HbA1c. However, obesity was
more common among rural patients. There were no significant differences in the use of
lipid-lowering, hypertensive, and diabetic medications between patients living in urban
and rural areas.
Both urban and rural women achieved recommended blood-pressure targets more
often than men. Women without established CVD were also more likely to achieve their
target LDL-C, non-HDL-C, and TG values than men.
In urban areas, more patients with hypertension achieved their therapeutic goals. The
same tendency was observed in patients with CVD attaining recommended LDL-C and
non-HDL-C targets in the male population.
Older age, male gender, co-existence of CV risk factors (e.g., excessive weight or
waist circumference, smoking, dyslipidaemia, hypertension, diabetes), and CVD, were
associated with a lower likelihood of reaching therapeutic levels of LDL-C, BP, and glucose
both in urban and rural populations. Of these factors, diagnosed CVD was most strongly
associated with failure to reach therapeutic LDL-C goals. Obesity was strongly negatively
associated with the achievement of therapeutic goals for BP and glucose.
4.2. Comparison with Other Studies
Poland is classified as a country with high CVD mortality [22]. Furthermore, several
studies have observed high CVD morbidity and a high prevalence of CV risk factors
in Poland.
The NATPOL2011 study, which was conducted in Poland in 2011, showed that the
prevalence of hypercholesterolaemia was 63.6% in villages, 55% in towns, with
50,000–200,000 citizens, and 59.5% in towns with >200,000 citizens [23]. The WOBASZ
study measured the prevalence, in big Polish cities, of CVD risk factors such as overweight
(47.9% in men, 39.0% in women), obesity (23.3% in men, 26.8% in women), HTN (68.8% in
men, 58.3% in women), hypercholesterolemia (82.6% in men, 87.4% in women), and DM
(10.4% in men, 8.6% in women) [24]. In our study, the prevalence of obesity, dyslipidaemia,
and diabetes was higher since the population of LIPIDOGRAM2015 does not represent the
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general population of Poland, like the studies mentioned above, but those attending PHC
practices.
In 2018, Nowicki et al. published the results of a study conducted on 4040 inhabitants
of Eastern Poland, aged 35–64, without a prior history of CV events [25]. Residents of
urban areas more frequently achieved recommended levels of BMI (27 vs. 22%), BP (12 vs.
9%), fasting cholesterol (38 vs. 35%), and fasting glucose (66 vs. 59%) than people living in
rural areas. The prevalence of obesity was higher in rural areas (31 vs. 38%). Compared
with our study, greater differences between the city and the countryside can be explained
by the method of recruiting patients (population selected from the electoral record) and the
fact that the study was conducted in a less-developed region than the Polish average.
There are also some differences in the prevalence of CVD and CV risk factors between
urban and rural populations in European countries and the United States.
In 2011, Markowić et al. published a study of 2467 participants ≥40 years old, who
visited their general practitioner for any reason. The study included 59 general practices,
covering all of Croatia [6]. Participants from rural areas had significantly higher systolic
and diastolic BP, while no clinically relevant differences in cholesterol fraction levels (TC,
LDL-C, HDL-C, and TG) were observed. Obesity was more common in rural patient
populations, both in the continental (35 vs. 45%) and coastal (32 vs. 36%) areas.
Lindroth et al. showed that the overweight and obesity rates were higher in rural than
urban areas (43 vs. 37% and 26 vs. 19%, respectively). The differences in SBP, DBP, and
fasting glucose levels were not statistically significant. Cholesterol levels were lower in
cities than in the countryside, although the difference was minor (5.4 vs. 5.8 mmol/L in
males and 5.4 vs. 5.8 mmol/L in females) [7].
The U.S. Atherosclerosis Risk in Communities Study (ARIC) included white persons
aged 45–64 (n = 7497) selected in urban and semi-rural areas surveyed in 1987–1989. The
TC and BP levels in both populations were similar [26,27].
Overall, the most recent studies from various developed countries have reported
similar results to ours and have found minor differences in CVD risk factors between rural
and urban areas.
4.3. Interpretation of Study Results
The results of our study confirm previous observations in relation to the high preva-
lence of CVD and CV risk factors in the Polish population. This is true in both urban and
rural areas. Although there are differences in the prevalence of CV risk factors between
urban and rural populations in Poland, these differences in BP, cholesterol fractions, and
glucose levels are small. Nevertheless, these differences should be taken into account from
the public health point of view. They may be explained by differences in patients’ living
conditions and lifestyles. Differences may also reflect disparities in access to healthcare, as
described in other European studies [6,7]. Although we did not analyse these factors, they
should be taken into account when interpreting our findings.
Our study results showed that less than half of hypertensive patients and less than
10% of patients with CVD are reaching therapeutic goals for LDL-C. Those values are far
from satisfactory and indicate a clear need for improvements in care. Pharmacotherapy
used in the treatment of CVD, hypertension, and diabetes is similar in Polish urban and
rural areas.
4.4. Implications of Study Results
The results of our study may be important for family doctors and their patients.
Only around 50% of primary care patients in Poland achieve recommended targets for
BP, glucose, and HbA1c. Of particular concern is the very low percentage of patients
with CVD reaching the therapeutic level of LDL-C. Thus, it is necessary to put more
emphasis on (1) understanding disease states and their implications for long-term health,
(2) educating patients about the efficacy and importance of any drugs they are prescribed,
and (3) emphasizing the importance of long-term adherence to drugs, lifestyle modification,
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and clinical follow-up in order to optimize health care and management of CV risk factors.
Concerning lipids, it is essential to encourage physicians to implement more effective
management of patients, focusing on lifestyle changes and, when required, the use of
combination therapy and share care arrangements with other specialists. Since the use of
ezetimibe is suboptimal, PHC physicians should put more emphasis on combined statin–
ezetimibe therapy. Particular attention should be paid to older men with a low level of
education and obese patients, especially in rural areas. We are currently seeing a trend
towards lowering the target values of cholesterol and blood pressure (introduced in 2018
and 2019 by ESC guidelines) [20,21]. After analysing our data in light of those new target
values, we see the further need to implement more effective management of patients.
The results of our study are of interest to public health specialists. The high preva-
lence of CV risk factors and problems with achieving therapeutic goals indicate that the
existing care and implemented national prevention programs are insufficient. The results
of our study indicate that patients from rural areas likely have unrecognized obstacles to
achieving target levels of BP, LDL-C, and non-HDL-C. It seems advisable to develop a
patient information program and an educational agenda aimed at medical staff to improve
the situation.
Researchers should plan and perform additional systematic studies on CVD and CV
risk factor prevalence in the Polish PHC patient population. Such follow-up studies will
help to assess whether the situation is changing in the desired direction.
5. Conclusions
The prevalence of CVD and CV risk factors among urban and rural adult populations
attending primary care in Poland is high. There were no important differences in the
prevalence of hypertension, diabetes, dyslipidaemia, and CVD between those groups,
while obesity was found to be slightly more common in rural areas. Patients with CVD, in
particular, have difficulties in achieving LDL-C target goals, while the rural male population
with hypertension has less well-controlled BP. Therefore, there is a need to implement CVD
prevention programs in Polish primary care aimed both at urban and rural areas residents,
with greater attention paid to the rural population.
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0018/2015) and conforms to the principles outlined in the Declaration of Helsinki.
Informed Consent Statement: All participants signed informed consent and gave their permission
to use their anonymised data for the purpose of the scientific studies.
J. Clin. Med. 2021, 10, 5656 11 of 12
Data Availability Statement: The data underlying this article will be shared on reasonable request
to the corresponding author.
Acknowledgments: We would like to thank all volunteer LIPIDOGRAM2015 investigators, all
volunteer staff, and all participants. The list of the LIPIDOGRAM2015 Investigators is presented
in S1.
Conflicts of Interest: J.J.J. and M.B. have received an unrestricted educational grant from Valeant,
and served as a consultant or speaker for Valeant. T.T. has served as a consultant or speaker for
Boehringer Ingelheim, Biofarm, AstraZeneca, Novo Nordisk Pharma. P.E.P. owns four shares in
AstraZeneca PLC and has received honoraria and/or travel reimbursement for events sponsored by
AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp, and Sanofi. D.P.M. has given talks, acted as
a consultant, or attended conferences sponsored by Amgen, Novo Nordisk, and Libytec. All other
authors have no conflict of interest concerning the results of this analysis. The funders had no role
in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the
manuscript, or in the decision to publish the results.
References
1. Hartley, D. Rural health disparities, population health, and rural culture. Am. J. Public Health 2004, 94, 1675–1678. [CrossRef]
2. Bragg, F.; Holmes, M.V.; Iona, A.; Guo, Y.; Du, H.; Chen, Y.; Bian, Z.; Yang, L.; Herrington, W.; Bennett, D.; et al. Association
between diabetes and cause-specific mortality in rural and urban areas of China. JAMA J. Am. Med. Assoc. 2017, 317, 280–289.
[CrossRef] [PubMed]
3. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in
195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392,
1736–1788. [CrossRef]
4. Wilkins, E.; Wilson, L.; Wickramasinghe, K.; Bhatnagar, P.; Leal, J.; Luengo-Fernandez, R.; Burns, R.; Rayner, M.; Townsend, N.
European Cardiovascular Disease Statistics 2017; European Heart Network: Brussels, Belgium, 2017.
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lidis, D.; et al. Design and rationale of a nationwide screening analysis from the LIPIDOGRAM2015 and LIPIDOGEN2015
studies. Arch. Med. Sci. 2020, 1–13. [CrossRef]
14. Tykarski, A.; Narkiewicz, K.; Gaciong, Z.; Januszewicz, A.; Litwin, M.; Kostka-Jeziorny, K.; Adamczak, M.; Szczepaniak-Chicheł,
L.; Chrostowska, M.; Czarnecka, D.; et al. 2015 guidelines for the management of hypertension. Recommendations of the Polish
Society of Hypertension—Short version. Kardiol. Pol. 2015, 73, 676–700. [CrossRef] [PubMed]
15. Reiner, Z.; Catapano, A.L.; De Backer, G.; Graham, I.; Taskinen, M.-R.; Wiklund, O.; Agewall, S.; Alegria, E.; Chapman, M.J.;
Durrington, P.; et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of
dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011,
32, 1769–1818. [CrossRef] [PubMed]
J. Clin. Med. 2021, 10, 5656 12 of 12
16. Czech, A.; Cypryk, K.; Czupryniak, L.; Gajewska, D.; Grzeszczak, W.; Gumprecht, J.; Idzior-Waluś, B.; Jaosz-Chobot, P.; Kalarus,
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